Stocks Health care BMRA

NASDAQ · Health care

Biomerica Inc (BMRA)

Biomerica Inc reported revenue of $4.5M in fiscal 2026, down 16.2% from a year earlier. It posted a net loss of $3.8M. At May 31, 2026 it held $1.3M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on August 31, 2026.

Watch BMRA in 60 seconds

What Biomerica Inc does

Biomerica Inc is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker BMRA.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Where BMRA ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Biomerica Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 24, 2026
   Shelf registration to sell securities S-3
2. September 24, 2026
   Shelf registration to sell securities S-3
3. August 31, 2026
   Annual report 10-K · period to May 31, 2026Revenue fell 16% to $4.5M versus the prior year; diluted EPS -$1.30 versus -$2.16.
4. August 26, 2026
   Material agreement 8-K
5. June 4, 2026
   Material agreement 8-K
6. April 13, 2026
   Quarterly report 10-Q · period to February 28, 2026Revenue fell 12% to $987K versus the same quarter last year; diluted EPS -$0.44 versus -$0.48.
7. February 27, 2026
   Employee stock plan registration S-8
8. January 14, 2026
   Quarterly report 10-Q · period to November 30, 2025Revenue fell 26% to $1.2M versus the same quarter last year; diluted EPS -$0.45 versus -$0.06.
9. December 16, 2025
   Shareholder vote results 8-K
10. October 23, 2025
    Additional proxy material DEFA14A

Recent insider filings (Forms 3, 4 and 144): 9, the latest on September 8, 2026. Insider transactions on SEC

Insider trades

What the people running Biomerica Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $158K worth of shares on the open market in the last 90 days and sold none.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BMRA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 446,737 shares in total.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BMRA

What does Biomerica Inc do?

Biomerica Inc is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker BMRA.

Is Biomerica Inc profitable?

No. In fiscal 2026 it reported a net loss of $3.8M on revenue of $4.5M.

How much revenue does Biomerica Inc make?

In fiscal 2026 Biomerica Inc reported revenue of $4.5M. That is 16.2% less than a year earlier.

When did Biomerica Inc last report?

Its most recent periodic report is the annual report (10-K) filed on August 31, 2026. It covers the period to May 31, 2026. Its newest filing of any kind is the shelf registration to sell securities from September 24, 2026.

Similar companies

Compare BMRA with

Compare BMRA with any company

Follow BMRA

Get an email when Biomerica Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow BMRA: get an email when it files

Where the numbers come from

Financial figures are the values Biomerica Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.